Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

An amendment to this paper has been published and can be accessed via the original article.

Bibliographic Details
Main Authors: Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Yi-Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi, Emi Yamada
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Arthritis Research & Therapy
Online Access:http://link.springer.com/article/10.1186/s13075-020-02247-3

Similar Items

Similar Items